[ad_1] Nano cap OncBioMune Pharmaceuticals (OTCPK: OBMP + 14.8% ) is up below the average news volume that it has engaged a CRO to handle a Phase 2 clinical trial evaluating the …
Read More »OncBioMune goes with the mid-stage study of the therapeutic vaccine against prostate cancer; up 15% – OncBioMune Pharmaceuticals, Inc. (OTCMKTS: OBMP)
